Salvage radiotherapy (sRT) is the standard of care for biochemical recurrence of prostate cancer when prostate-specific antigen (PSA) levels reach 0.1–0.2 ng/mL after radical prostatectomy. However, conventional imaging (bone scan, CT, MRI) has limited sensitivity at PSA levels below 1 ng/mL. A retrospective study evaluated how prostate-specific membrane antigen (PSMA) PET/CT–guided management influences treatment decisions and outcomes following sRT. With a median follow-up of 59.4 months in 113 patients, the median PSA at restaging was 0.4 ng/mL, occurring a median of 19.9 months after surgery.
PSMA PET/CT classified 16.8% as TrN0M0, 28.3% as N1M0, 14.2% as M1, and 40.7% as T0N0M0. Based on these findings, 67.3% received androgen deprivation therapy (ADT), and 55.8% underwent whole-pelvis radiotherapy (WPRT). Disease progression occurred in 50.4% of patients. Median progression-free…
